Prenetics Group Limited (PRE)
NASDAQ:PRE
Want to see PRE full AI Analyst Report?
PRE Stock Chart & Stats
$17.83
-$0.22(-3.97%)
At close: 4:00 PM EST
$17.83
-$0.22(-3.97%)
Day’s Range― - ―
52-Week Range$5.58 - $23.63
Previous CloseN/A
Volume5.03K
Average Volume (3M)238.85K
Market Cap
$355.08M
Enterprise Value$328.78M
Total Cash (Recent Filing)$61.49M
Total Debt (Recent Filing)$2.20M
Price to Earnings (P/E)―
Beta0.15
Next Earnings
Sep 11, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.02
Shares Outstanding15,247,465
10 Day Avg. Volume324,308
30 Day Avg. Volume238,846
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)1.27
Price to Sales (P/S)2.40
P/FCF Ratio-10.05
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue3.46
Enterprise Value/Gross Profit6.52
Enterprise Value/Ebitda-8.02
Forecast
1Y Price Target
$32.50Price Target Upside82.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.09
Revenue Forecast (FY)$191.89M
Bulls Say, Bears Say
Bulls Say
Revenue Acceleration And Margin ExpansionSustained top-line re-acceleration and materially higher gross margins reflect scale in manufacturing, favorable mix toward high-margin SKUs, and packaging/fulfillment gains. These structural margin improvements increase the odds management can convert revenue growth into lasting operating leverage as IM8 scales globally.
Subscription-first Model With Improving Cohort EconomicsA subscription-led revenue base with rising AOV and faster cohort payback creates predictable recurring cash flows and higher lifetime value. Durable subscription retention and accelerating cohort economics underpin scalable unit economics, reducing reliance on one-time sales and supporting margin sustainability as the business internationalizes.
Strong Liquidity And Low Leverage To Fund GrowthA strengthened balance sheet and minimal debt provide a multi-quarter runway to fund international marketing, product rollouts, and operating investments without immediate refinancing. This lowers short-term funding risk and gives management flexibility to pursue strategic investments and execute on IM8's growth roadmap.
Bears Say
Persistent Operating Losses And Negative Cash FlowMulti-year negative operating and free cash flow indicate the business still burns cash to grow. Until scale economics convert into positive operating cash generation, the company remains reliant on existing liquidity or future funding, elevating dilution and execution risk despite improving margins and revenue.
High Marketing Spend And Customer Acquisition ConcentrationLarge, concentrated marketing outlays can compress returns if platform costs rise or if channel performance deteriorates. Heavy dependence on a single ad platform increases scaling risk and could force higher CAC or slower growth if diversification to TikTok/YouTube/AppLovin does not scale efficiently.
Reporting Clarity Issues And Preliminary Accounting ItemsInconsistent guidance and outstanding non-cash accounting items create transparency and forecasting risks. This can impair investor confidence, complicate capital allocation, and mask underlying operational performance if final adjustments materially alter reported metrics or the timing of recognized gains/losses.
Prenetics Group News
PRE FAQ
What was Prenetics Group Limited’s price range in the past 12 months?
Prenetics Group Limited lowest stock price was $5.58 and its highest was $23.63 in the past 12 months.
What is Prenetics Group Limited’s market cap?
Prenetics Group Limited’s market cap is $355.08M.
When is Prenetics Group Limited’s upcoming earnings report date?
Prenetics Group Limited’s upcoming earnings report date is Sep 11, 2026 which is in 103 days.
How were Prenetics Group Limited’s earnings last quarter?
Prenetics Group Limited released its earnings results on May 14, 2026. The company reported -$1.135 earnings per share for the quarter, missing the consensus estimate of -$0.835 by -$0.3.
Is Prenetics Group Limited overvalued?
According to Wall Street analysts Prenetics Group Limited’s price is currently Undervalued.
Does Prenetics Group Limited pay dividends?
Prenetics Group Limited pays a Quarterly dividend of $0.7 which represents an annual dividend yield of N/A. See more information on Prenetics Group Limited dividends here
What is Prenetics Group Limited’s EPS estimate?
Prenetics Group Limited’s EPS estimate is -0.84.
How many shares outstanding does Prenetics Group Limited have?
Prenetics Group Limited has 15,247,465 shares outstanding.
What happened to Prenetics Group Limited’s price movement after its last earnings report?
Prenetics Group Limited reported an EPS of -$1.135 in its last earnings report, missing expectations of -$0.835. Following the earnings report the stock price went up 0.114%.
Which hedge fund is a major shareholder of Prenetics Group Limited?
Currently, no hedge funds are holding shares in PRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prenetics Group Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$32.50 (82.28% Upside)
$32.50 (82.28% Upside)
Blogger Sentiment
Bullish
PRE Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 24.5%
Last 30 Days ▼ 24.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
111.00%
12-Months-Change
Fundamentals
Return on Equity
-36.02%
Trailing 12-Months
Asset Growth
-3.51%
Trailing 12-Months
Company Description
Prenetics Group Limited
Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
PRE Company Deck
PRE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strongly positive operational narrative: very high revenue growth, significant improvement in gross margins, rapid cohort/LTV acceleration, healthy subscriber growth and consumption, raised guidance, and substantial cash resources after a Bitcoin sale. Management acknowledged near-term EBITDA losses driven by deliberate marketing investments to scale international quarterly subscriptions and noted preliminary accounting items pending close. Execution risks remain around channel diversification, potential reporting clarity, and delivering new product launches. On balance the positive growth, improving unit economics, and strong cohort metrics outweigh the near-term losses and execution items.View all PRE earnings summariesPRE Stock 12 Month Forecast
Average Price Target
$32.50
▲(82.28% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.04% Mutual Funds
7.00% Other Institutional Investors
92.75% Public Companies and
Individual Investors